Management of lower urinary tract symptoms in patients with benign prostatic hyperplasia during COVID-19. results of an all-russian observational study “ATLANT”
- Authors: Neymark B.A1, Neymark A.I1, Yakovets Y.V1, Nozdrachev N.A1, Ibishev K.S2, Kuzmin I.V3
-
Affiliations:
- Federal State Budgetary Educational Institution of Higher Education «Altay State Medical University» of the Ministry of Healthcare of Russian Federation
- Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University of the Ministry of Health of Russia
- Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation»
- Issue: No 1 (2022)
- Pages: 28-34
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312789
- DOI: https://doi.org/10.18565/urology.2022.1.28-34
- ID: 312789
Cite item
Open Access
Access granted
Abstract
Background. COVID-19 aggravates lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). The optimal treatment regimen for patients with this disease during the COVID-19 pandemic is still under question. Objectives. The aim of the All-Russian observational study of Afalaza in the Treatment of LUTS in pAtieNTs with BPH during COVID-19 (ATLANT) was to obtain additional data on the efficacy and safety of Afalaza in this patient group. Methods. The study enrolled 73 men aged 46-65 years with LUTS and diagnosed BPH who suffered from COVID-19. All patients received Afalaza for 16 weeks. The dynamics of BHP indicators, erectile function, and quality of life were assessed after 4, 12, and 16 weeks of treatment. Results. Patients with LUTS/BHP who suffered from COVID-19 had a decrease in the total IPSS score from 21.6+8.6 to 6.4±2.4 (-70.4%) points after 16 weeks of treatment. There was a direct correlation between COVID-19 duration (and beginning of therapy) and the severity of symptoms after Afalaza treatment. According to the subjective assessment of patients, there was a significant increase in the quality of life and erectile function after 16 weeks of treatment. 9 mild AEs were registered in 12.3% of patients and were unrelated to the study drug. Conclusions. Results show that Afalaza may be a perspective drug for the treatment of LUTS/BPH in patients with COVID-19 and be used for this urological disease in the current COVID-19 pandemic.
Full Text
About the authors
B. A Neymark
Federal State Budgetary Educational Institution of Higher Education «Altay State Medical University» of the Ministry of Healthcare of Russian Federation
Email: urologagmu@maii.ru
Dr. Med. Sci., Professor of the department of urology Barnaul, Russia
A. I Neymark
Federal State Budgetary Educational Institution of Higher Education «Altay State Medical University» of the Ministry of Healthcare of Russian Federation
Email: urologagmu@mail.ru
Dr. Med. Sci., Professor of the department of urology Barnaul, Russia
Ya. V Yakovets
Federal State Budgetary Educational Institution of Higher Education «Altay State Medical University» of the Ministry of Healthcare of Russian Federation
Email: yyakovec@mail.ru
Саndidate оf Med. Sci., Docent of the department of urology Barnaul, Russia
N. A Nozdrachev
Federal State Budgetary Educational Institution of Higher Education «Altay State Medical University» of the Ministry of Healthcare of Russian Federation
Email: urologagmu@mail.ru
Саndidate оf Med. Sci., Docent ofthe department of urology Barnaul, Russia
Kh. S Ibishev
Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University of the Ministry of Health of Russia
Email: ibishev22@mail.ru
Dr. Med. Sci., Professor of the Department of Urology and Human Reproductive Health (with a course of pediatric urology and andrology) Rostov-on-Don
I. V Kuzmin
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation»
Email: kuzminigor@mail.ru
Dr. Med. Sci., professor of the department of urology Saint Petersburg, Russia
References
- Barello S., Palamenghi L., Graffigna G. Burnout and somatic symptoms among frontline healthcare professionals at the peak of the Italian COVID-19 pandemic. Psychiatry Res. 2020;290:113129. doi: 10.1016/j.psychres.2020.113129. Epub 2020 May 27. PMID: 32485487; PMCID: PMC7255285.
- Haghpanah A., Masjedi F., Salehipour M., Hosseinpour A., Roozbeh J., Dehghani A. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review. Prostate Cancer Prostatic Dis. 2021;18:1-12. doi: 10.1038/s41391-021-00388-3. Epub ahead of print. PMID: 34007019; PMCID: PMC8129694.
- Nabeeh H., Ibrahim A., Taha D.E., Talaat M., Abdelbaky T.M. Impact of COVID-19 pandemic on lower urinary tract symptoms in patients with benign prostatic hyperplasia and predictors of urine retention in such patients. Low Urin Tract Symptoms. 2021 Aug 26. doi: 10.1111/luts.12407. Epub ahead of print. PMID: 34435456.
- Can O., Erkoç M., Ozer M., Karakanli M.U., Otunctemur A. The effect of COVID-19 on lower urinary tract symptoms in elderly men.Int J Clin Pract. 2021;75(6):e14110. doi: 10.1111/ijcp.14110.
- Karabulut I., Cinislioglu A. E., Cinislioglu N., et al. The Effect of the Presence of Lower Urinary System Symptoms on the Prognosis of COVID-19: Preliminary Results of a Prospective Study [published correction appears in Urol Int. 2020;16:1-2]. Urol Int. 2020;104(11-12):853-858. doi: 10.1159/000510761
- Michel F., Gaillet S., Cornu J.N., Robert G., Game X., Phe V., Karsenty G.Comite de neuro-urologie-CUROPF-CTMH de l’AFU. Recommandations jointes des comites de l’AFU (neuro-urologie, CUROPF, CTMH) pour l’urologie fonctionnelle durant la crise sanitaire liee au COVID-19 [French Association of Urology. COVID-19: Recommendations for functional urology]. Prog Urol. 2020;30(8-9):414-425. French. doi: 10.1016/j.purol.2020.04.007. Epub 2020 Apr 20. PMID: 32418734; PMCID: PMC7167583.
- Medina-Polo J., Teigell Tobar J., Romero-Otero J., Carballido-Rodriguez J., Dominguez-Esteban M., Martinez-Berganza M.L., Minana-Lopez B., Unda Urzaiz J.M., Rodriguez-Antolin A. Manejo de la hiperplasia benigna de prostata durante la pandemia COVID-19 [Benign prostatic hyperplasia management during COVID-19 pandemia.]. Arch Esp Urol. 2020;73(5):405-412. Spanish. PMID: 32538810.
- Инструкция по медицинскому применению препарата Афалаза (РУ № ЛП-N (000021)-(Pr-RU)). [https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f32709ba-0177-40ef-9ba1-42731874f30a&t=]. Ссылка активна на 12.01.2022.
- Pushkar D., Vinarov A., Spivak L., Kolontarev K., Putilovskiy M., Andrianova E., Epstein О. Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, doubleblind, placebo-controlled, randomized clinical trial. Central European Journal of Urology. 2018.71(4):427-435. doi: 10.5173/ceju.2018.1803.
- Куприянов Ю.А., Раснер П.И., Рохликов И.М., Акрикиди А.А., Соловьев В.В., Марков А.А., Ноздрин Е.В., Логвинов Л.А., Василевский Р.П., Скрупский К.С., Пушкарь Д.Ю., Путиловский М.А., Эпштейн О.И. Опыт применения препарата Афалаза для лечения симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы без предшествующей терапии. Урология. 2019;3:36-42. doi: 10.18565/urology.2019.3.00-00.
- COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (UK); 2020 Dec 18. PMID: 33555768.
- Kim J., Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004 Oct 1;93(2):233-241. doi: 10.1002/jcb.20228. PMID: 15368351.
- Bulut E.C., Erkoç K., Bulut D., Koparal M.Y., Çetin S. The effect of COVID-19 epidemic on the sexual function of healthcare professionals. Andrologia. 2021;53(3):e13971. doi: 10.1111/and.13971
- Ергаков Д.В., Мартов А.Г. Смещение парадигмы комбинированной терапии в условиях пандемии COVID-19. Урология. 2021;1:33-38. doi: 10.18565/urology.2021.1.33-38.
